Synbiotics and treatment of asthma: A Double-blind, Randomized, Placeboâ€Controlled Clinical Trial
Phase 2
Active, not recruiting
- Conditions
- Asthma (mild to moderate -based on GINA classification )Childhood Asthma,Asthma Control,Synbiotics,Probiotics,Kidilact
- Registration Number
- TCTR20180625002
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 3
Inclusion Criteria
Mild to moderate asthma
Exclusion Criteria
1-Any other major health issues or use of any treatment or therapy that might affect trials outcomes/results.
2-Those who could not commit to the protocol or unwilling to participate anymore
3-Medication side effects
4-Loss of contact
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method synbiotic compound Kidilact® generally alleviates the symptoms of asthma in children of 12 years. 6 months after enrollment Questionnaire (times patient used rescue medications/ outpatient visits / hospital admissions )
- Secondary Outcome Measures
Name Time Method drug side effects During the research (at least 6 months) Questioner